GLP-1 analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Christian P. R. Hackenberger (b. Osnabruck, 1976) is a German chemist. He is a professor of Chemical Biology at the Humboldt University of Berlin and heads the research unit Biomolecule Modification and Delivery at the Leibniz Research Institute for Molecular Pharmacology. He is a co-founder of the Munich-based biotech company Tubulis.
=== Somatostatin analogs === Octreotide is an analog of the peptide hormone somatostatin, which inhibits the production of the growth hormone as well as numerous peptide hormones of the gastrointestinal system, including insulin, glucagon, pancreatic polypeptide, gastric inhibitory polypeptide, and gastrin. Octreotide is used for suppression of the hormonal syndromes which accompany several pancreatic islet cell tumors, including the Zollinger-Ellison syndrome of gastrinoma and the chronic hypoglycemia of insulinoma. It is also effective in suppression of the carcinoid syndrome, caused by advanced or extra-gastrointestinal carcinoid tumors. Octreotide may also be used for treatment of severe diarrhea caused by 5-fluorouracil chemotherapy or radiation therapy.
=== Centrally-projecting neurons === As well as neuroendocrine neurons, the PVN contains interneurons and populations of neurons that project centrally (i.e., to other brain regions). The centrally-projecting neurons include
Sources: en.wikipedia.org
== Biography == For Valve, Morasky composed the music for Team Fortress 2, Portal (with Kelly Bailey), Left 4 Dead, Left 4 Dead 2 (including composing and playing the guitar, keyboard and bass for the fictional hard rock band Midnight Riders), Portal 2, Counter-Strike: Global Offensive, Half-Life: Alyx, and Counter-Strike 2. He also worked as a senior visual effects artist and technical director on The Lord of the Rings and The Matrix film trilogies. Morasky was part of the now-defunct hardcore punk/noise rock band Steel Pole Bath Tub, which he founded in 1986 with Dale Flattum. S.P.B.T. disbanded in 2002.
Many lichens disperse via symbiotic vegetative propagules such as soredia, isidia, or blastidia, but X. parietina lacks these structures and must re-establish its symbiotic state with each reproductive cycle. Instead, oribatid mites—Trhypochtonius tectorum and Trichoribates trimaculatus—serve as vectors, consuming X. parietina and dispersing its viable ascospores and photobiont cells through their faecal pellets. This facilitates both short- and long-distance dispersal. Despite lacking specialized vegetative propagules, X. parietina demonstrates sophisticated reproductive strategies that overcome the challenges of sexual reproduction in lichens. When germinating fungal spores spread across a substrate, they first form associations with common non-symbiotic algae (such as Pleurococcus), creating a preliminary "proto-lichen" stage. This widespread network increases the likelihood of encountering the Trebouxioid photobiont needed for proper thallus development. Additionally, the mycobiont can extract suitable algal partners from the soredia of other lichens, particularly Physcia species that often grow alongside X. parietina and contain compatible photobionts. Once contact is established with compatible Trebouxia cells, the mycobiont forms specialized structures called haustorial complexes that enable efficient nutrient exchange.
Icotrokinra, sold under the brand name Icotyde, is a medication used for the treatment of plaque psoriasis. It is a cyclic peptide that functions as a selective interleukin 23 (IL-23) receptor antagonist. It is a synthetic peptide that binds selectively to the IL-23 receptor (IL-23R) with high affinity and competitively antagonizes the binding of IL-23. It is an immunosuppressant and interleukin inhibitor. It is being developed by Johnson & Johnson. Icotrokinra was approved for medical use in the United States in March 2026.
The Union for the Defense of the Motherland and Freedom (Russian: Союз защиты Родины и Свободы) was an underground anti-Bolshevik organization active during the early stages of the Russian Civil War. It was formally established in March 1918 under the leadership of Boris Savinkov, although the idea for the organization had emerged in late 1917. Its creation was supported by elements of the Volunteer Army, including Generals Lavr Kornilov and Mikhail Alekseev. The organization sought to coordinate anti-Bolshevik resistance and prepare armed uprisings in central Russia. It is best known for its role in organizing the Yaroslavl Uprising, the Rybinsk Uprising, the Murom Uprising, and the Elatma Uprising in 1918. Although it established branches in several Russian cities, it was largely destroyed following the suppression of these revolts. A successor organization, the People's Union for the Defense of the Motherland and Freedom, was reconstituted in exile in 1921 and continued anti-Bolshevik underground activity until it was dismantled by the Soviet secret police in 1924. Savinkov himself was arrested in 1924 and died in OGPU custody in 1925.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
The lyophilized powder is dissolved in a suitable solvent, often sterile water or a buffered diluent, with gentle mixing rather than vigorous shaking. Foaming and shear should be avoided because they can promote aggregation. The resulting solution is then stored cold and protected from light.